Priority 19 from the Psoriasis PSP
| UNCERTAINTY: What is the best and most cost-effective way of monitoring an oral or biological therapy for psoriasis e.g. clinical review, blood tests and measurement of medicine/antibodies levels? (JLA PSP Priority 19) | |
|---|---|
| Overall ranking | 19 |
| JLA question ID | 0072/19 |
| Explanatory note | Not available for this PSP |
| Evidence |
Kromer, 2018 Some evidence for cost-effectiveness of biological therapy (ie high-cost treatment / high efficacy) presented. Several studies reviewed were sponsored by pharma. Some comparative data presented but future research recommended. |
| Health Research Classification System category | Skin |
| Extra information provided by this PSP | |
|---|---|
| Original uncertainty examples | What is the safe/optimal monitoring strategy for patients established on biologic therapy? |
| Submitted by | 6 uncertainties were submitted around this question |
| PSP information | |
|---|---|
| PSP unique ID | 0072 |
| PSP name | Psoriasis |
| Total number of uncertainties identified by this PSP. | 55 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 17 September 2018 |